A novel and selective poly (ADP-ribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathy.
Chemotherapy-induced neuropathy is the principle dose limiting factor requiring discontinuation of many chemotherapeutic agents, including cisplatin and oxaliplatin.About 30 to 40% of patients receiving chemotherapy develop pain and sensory changes.Given that poly (ADP-ribose) polymerase (PARP) inhibition has been shown to provide neuroprotection,